A multi-component crystal of penoxsulam and pyridinecarboxamide ligands, its preparation method and application
By preparing multi-component crystals of penoxsulam and pyridine carboxamide ligands, the problem of penoxsulam's low water solubility was solved, achieving efficient weed control and environmentally friendly processing, and reducing the amount of pesticide applied and production costs.
Patent Information
- Application Number
- CN202611530031.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-30
- Publication Date
- 2026-11-17
AI Technical Summary
The technical grade penoxsulam has extremely low water solubility, resulting in low bioavailability. It is also prone to being washed away by rainwater, causing significant environmental stress. Existing formulations are difficult to process and are not environmentally friendly.
Multi-component crystals of penoxsulam and pyridine carboxamide ligands were prepared by grinding reaction crystallization or solution crystallization to improve solubility and bioavailability.
It improves the solubility and bioavailability of penoxsulam, reduces the amount of pesticide to be applied, promotes the development of green formulations, and reduces environmental risks and production costs.
Smart Images

Figure CN123106686A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pesticide multi-component crystal technology, specifically to a multi-component crystal of penoxsulam and pyridine carboxamide ligands, its preparation method, and its application. Background Technology
[0002] 3-(2,2-difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-α,α,α-trifluoromethyl-2-sulfonamide (Penoxsulam) is a herbicide from the triazolopyrimidin sulfonamide family. The molecular formula of penoxsulam is C2. 16 H 14 F5N5O5S has the chemical structure shown in formula (I): (I) Penflusulfonamide is a weakly acidic compound (primarily due to the proton on the sulfonamide group) with a complex molecular structure containing fluorine atoms and heterocyclic nitrogen atoms. As an acetolactate synthase (ALS) inhibitor, it is widely used in paddy fields to control barnyard grass, Echinochloa crus-galli, and various broadleaf weeds. Due to its broad spectrum of weed control and high activity, it is currently one of the main herbicides used in paddy fields.
[0003] Currently, penoxsulam technical grade has the following drawbacks: 1. Extremely low water solubility. Penoxsulam technical grade has extremely low water solubility in acidic environments (pH=4-6), approximately 5-10 mg / L, and only about 5.7 mg / L at room temperature. This low solubility directly limits its dissolution and penetration rate on plant leaves, resulting in low bioavailability. After rainwater runoff, the pesticide is easily lost, and the pesticide that fails to enter the plant ultimately enters the soil and water bodies, causing environmental pressure. 2. Difficult formulation processing and solvent dependence. To solve the solubility problem, most current commercial formulations are oil suspensions (OD) or suspensions (SC). These formulations usually require the addition of large amounts of dispersants, emulsifiers, and organic solvents. This not only increases production costs, but the use of organic solvents also violates the development trend of "environmentally friendly formulations," and is prone to physical stability problems during long-term storage, such as paste formation, layering, and crystallization. The extremely low water solubility of penoxsulam technical grade leads to difficulties in pesticide formulation processing and low field bioavailability. In response, those skilled in the art often use physical compounding or adding large amounts of surfactants to prepare suspending agents, but problems such as environmental pollution and high cost still exist.
[0004] In summary, there is a need to develop a green and safe multi-component crystal of penoxsulam and pyridine carboxamide ligands, as well as its preparation method and application. Summary of the Invention
[0005] In view of the problems existing in the prior art, the present invention provides a multi-component crystal of penoxsulam and pyridine carboxamide ligands, its preparation method and application. The multi-component crystal of penoxsulam and pyridine carboxamide ligands has a molar ratio of penoxsulam to pyridine carboxamide ligands of 1:1, which is a novel solid form of penoxsulam. It can improve the solubility of penoxsulam without changing the covalent bonds of penoxsulam, thereby improving efficacy and bioavailability. Moreover, the present invention uses a grinding reaction crystallization method or a solution crystallization method to prepare the multi-component crystal of penoxsulam and pyridine carboxamide ligands. The process is simple, the conditions are mild, the reproducibility is good, and it is environmentally friendly, making it suitable for large-scale production.
[0006] To achieve this objective, the present invention adopts the following technical solution: One objective of this invention is to provide a multi-component crystal of penoxsulam and pyridine carboxamide ligands, wherein the molar ratio of penoxsulam to pyridine carboxamide ligands in the multi-component crystal is 1:1.
[0007] As a preferred embodiment of the present invention, the pyridine carboxamide ligand includes at least one of nicotinamide and isonicotinamide.
[0008] As a preferred embodiment of the present invention, the pyridine carboxamide ligand is nicotinamide; the multi-component crystal of penoxsulam and the pyridine carboxamide ligand is a multi-component crystal formed by combining penoxsulam and nicotinamide in a molar ratio of 1:1, and is triclinic with a space group of [missing information]. The unit cell parameters are a = 8.6677(2) Å, b = 10.4916(3) Å, c = 13.9465(3) Å, α = 93.0866(17)°, β = 99.1415(19)°, γ = 97.684(2)°, unit cell volume V =1237.26(5) Å 3 , Z = 2.
[0009] As a preferred technical solution of the present invention, the multi-component crystal formed by combining penoxsulam and nicotinamide in a molar ratio of 1:1 exhibits diffraction peaks at 2θ values of 8.4°±0.2°, 10.4°±0.2°, 13.4°±0.2°, 14.4°±0.2°, 15.8°±0.2°, 20.3°±0.2°, 21.2°±0.2°, 24.7°±0.2°, 25.6°±0.2°, and 26.5°±0.2° in the X-ray powder diffraction pattern; and a characteristic melting peak is observed at 156.4±2℃ in the differential scanning calorimetry pattern.
[0010] As a preferred embodiment of the present invention, the pyridinecarboxamide ligand is isonicotinamide; the multi-component crystal of penoxsulam and the pyridinecarboxamide ligand is a multi-component crystal formed by combining penoxsulam and isonicotinamide in a molar ratio of 1:1, and is triclinic with a space group of [missing information]. The unit cell parameters are a = 8.5668(2) Å, b = 12.3085(11) Å, c = 12.6054(12) Å, α = 70.212(9)°, β = 86.276(5)°, γ = 80.245(5)°, cell volume V = 1232.56(18) Å 3 , Z = 2.
[0011] As a preferred technical solution of the present invention, the multi-component crystal formed by combining penoxsulam and isonicotinamide in a molar ratio of 1:1 exhibits diffraction peaks at 2θ values of 12.0°±0.2°, 12.9°±0.2°, 15.4°±0.2°, 18.9°±0.2°, 22.4°±0.2°, 28.3°±0.2°, and 32.5°±0.2° in the X-ray powder diffraction pattern; and a characteristic melting peak is observed at 126.3±2℃ in the differential scanning calorimetry pattern.
[0012] A second objective of this invention is to provide a method for preparing multi-component crystals of penoxsulam and pyridine carboxamide ligands according to one objective, wherein the preparation method includes a grinding reaction crystallization method or a solution crystallization method.
[0013] As a preferred embodiment of the present invention, the grinding reaction crystallization method satisfies at least one of the following (1)-(6): (1) Weigh penoxsulam and pyridine carboxamide ligands at a molar ratio of 1:1, grind them separately for the first time, mix them and add a good solvent, grind them for the second time, and dry them to obtain multi-component crystals of penoxsulam and pyridine carboxamide ligands; (2) Based on a total addition of 100 mg of penoxsulam and pyridine carboxamide ligands, the amount of good solvent added is 0.1-3 mL; (3) The good solvent includes any one or a combination of at least two of acetonitrile, acetone, methanol, dichloromethane, ethanol or tetrahydrofuran; (4) The time for the first grinding is 2-10 min; (5) The second grinding time is 20-40 min; (6) The drying temperature is 25-60℃.
[0014] As a preferred embodiment of the present invention, the solution crystallization method satisfies at least one of the following (a)-(h): (a) Weigh penoxsulam and pyridine carboxamide ligands at a molar ratio of 1:1, add them to a good solvent to form a suspension, stir, separate the solid and liquid and dry to obtain multi-component crystals of penoxsulam and pyridine carboxamide ligands; (b) Weigh penoxsulam and pyridine carboxamide ligands at a molar ratio of 1:1, add them to a good solvent to form a clear solution, add a poor solvent, stir, separate the solid and liquid and dry to obtain multi-component crystals of penoxsulam and pyridine carboxamide ligands; (c) Weigh penoxsulam and pyridine carboxamide ligands at a molar ratio of 1:1, add them to a good solvent to form a clear solution, stir, cool and cool until solid precipitates, separate the solid and liquid and dry to obtain multi-component crystals of penoxsulam and pyridine carboxamide ligands; (d) Based on a total addition of 100 mg of penoxsulam and pyridine carboxamide ligands, the amount of good solvent added is 1-20 mL; (e) The good solvent includes any one or a combination of at least two of acetonitrile, acetone, methanol, dichloromethane, ethanol or tetrahydrofuran; (f) The undesirable solvents include any one or a combination of at least two of ethyl acetate, isopropanol, water or methyl tert-butyl ether; (g) The drying temperature is 25-60℃; (h) The stirring rate is 100-500 rpm.
[0015] The third objective of this invention is to provide an application of a multi-component crystal of penoxsulam and pyridine carboxamide ligands, wherein the multi-component crystal of penoxsulam and pyridine carboxamide ligands described in the first objective, or the multi-component crystal of penoxsulam and pyridine carboxamide ligands prepared by the preparation method described in the second objective, is applied to herbicides.
[0016] The fourth objective of this invention is to provide a method for preparing single crystals of a multi-component crystal of penoxsulam and pyridinecarboxamide ligands, wherein the single crystal preparation method includes: Prepare multi-component crystals of penoxsulam and pyridine carboxamide ligands, add them to a good solvent, heat to dissolve, separate the solid and liquid to obtain the liquid, evaporate the liquid to obtain single crystals of multi-component crystals of penoxsulam and pyridine carboxamide ligands.
[0017] Furthermore, the good solvent includes any one or a combination of at least two of acetonitrile, acetone, methanol, dichloromethane, ethanol, or tetrahydrofuran.
[0018] Furthermore, the liquid evaporates at a temperature of 10-40°C for 3-30 days.
[0019] Compared with existing technical solutions, the present invention has at least the following beneficial effects: (1) This invention, from the perspective of supramolecular crystal engineering, first prepared a multi-component crystal of penoxsulam and pyridine carboxamide ligands, and developed a new solid form of penoxsulam, which has practical application value such as reducing dosage and increasing efficiency.
[0020] (2) The multi-component crystals of penoxsulam and pyridine carboxamide ligands described in this invention can improve bioavailability: the highly soluble multi-component crystals can significantly improve herbicidal activity, which means that under the premise of achieving the same herbicidal effect, the amount of pesticide applied per acre can be reduced, directly responding to the national call for "reduction of pesticide use".
[0021] (3) The multi-component crystals of penoxsulam and pyridine carboxamide ligands described in this invention can promote the development of green formulations: the improvement of physicochemical properties makes penoxsulam easier to process into water-based or solid formulations, reducing the use of organic solvents, reducing environmental risks and production costs. Attached Figure Description
[0022] Figure 1 This is the XRD pattern of the active pharmaceutical ingredient penoxsulam.
[0023] Figure 2 These are the DSC and TGA graphs of the active pharmaceutical ingredient penoxsulam.
[0024] Figure 3 This is the crystal structure diagram of the sample obtained in Example 1 of the present invention.
[0025] Figure 4 This is an XRD comparison image of the sample obtained in Example 1 of the present invention.
[0026] Figure 5 These are the DSC and TGA images of the sample obtained in Example 1 of this invention.
[0027] Figure 6 This is the crystal structure diagram of the sample obtained in Example 6 of the present invention.
[0028] Figure 7 This is an XRD comparison image of the sample obtained in Example 6 of the present invention.
[0029] Figure 8 These are the DSC and TGA images of the sample obtained in Example 6 of this invention. Detailed Implementation
[0030] It should be noted that the following detailed descriptions are exemplary and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The technical solutions of the present invention are further illustrated below through specific embodiments. Those skilled in the art should understand that the embodiments described are merely illustrative of the present invention and should not be construed as specific limitations thereof.
[0031] This invention is intended to cover all alternatives, modifications, and equivalent technical solutions, all of which are included within the scope of the invention as defined in the claims. Those skilled in the art will recognize that many similar or equivalent methods and materials described herein can be used to practice this invention. This invention is by no means limited to the methods and materials described herein. In the event that one or more of the incorporated documents, patents, and similar materials differ from or contradict this application (including, but not limited to, defined terminology, application of terminology, described techniques, etc.), this application shall prevail.
[0032] It should be further appreciated that certain features of the invention, for clarity, have been described in multiple independent embodiments, but may also be provided in combination in a single embodiment. Conversely, various features of the invention, for brevity, have been described in a single embodiment, but may also be provided individually or in any suitable sub-combination.
[0033] Unless otherwise stated, all technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art. All patents and publications related to this invention are incorporated herein by reference in their entirety.
[0034] Unless otherwise stated, the following definitions shall apply as used herein. For the purposes of this invention, chemical elements are consistent with the CAS version of the periodic table and the 75th edition of the *Handbook of Chemistry and Physics*, 1994. Furthermore, general principles of organic chemistry can be found in *Organic Chemistry*, Thomas Sorrell, University Science Books, Sausalito: 1999, and *March's Advanced Organic Chemistry* by Michael B. Smith and Jerry March, John Wiley & Sons, New York: 2007, the entire contents of which are incorporated herein by reference.
[0035] The terms “comprising” or “including” are open-ended expressions, meaning they include the contents specified in this invention but do not exclude other aspects.
[0036] The term "multicomponent crystal" refers to a crystal composed of two or more phases; a phase is something that has the same composition, crystal structure, and properties.
[0037] The term "XRD pattern" or "PXRD" refers to an X-ray powder diffraction pattern.
[0038] The term "substantially as shown" means that a substantially pure "crystal form" has at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 99% of its peaks appearing in the given X-ray powder diffraction pattern. As the content of a certain crystal form in a sample gradually decreases, some diffraction peaks attributable to that crystal form in the X-ray powder diffraction pattern may decrease due to factors such as the instrument's detection sensitivity.
[0039] The term "relative intensity" refers to the ratio of the intensity of the other peaks to the intensity of the first strongest peak in a set of diffraction peaks belonging to a certain crystal form, when the intensity of the first strongest peak is defined as 100%.
[0040] In the context of this invention, the 2θ (also known as 2theta or diffraction peak) values in X-ray powder diffraction patterns are expressed in degrees (°).
[0041] When referring to spectra and / or data in figures, the term "diffraction peak" refers to a feature that a person skilled in the art would not attribute to background noise.
[0042] The measurement of the 2θ or diffraction peaks in the X-ray powder diffraction pattern of the crystal is subject to experimental error. The measurement of the 2θ or diffraction peaks in the X-ray powder diffraction pattern may vary slightly between different machines and between different samples. The experimental error or difference may be + / - 0.2 units, + / - 0.1 units, or + / - 0.05 units. Therefore, the value of the 2θ or diffraction peaks cannot be considered absolute.
[0043] The differential scanning calorimetry (DSC) curve of the crystal has experimental errors. The position and peak value of the endothermic peak may vary slightly between one machine and another, and between one sample and another. The experimental error or difference may be less than or equal to 5°C, or less than or equal to 4°C, or less than or equal to 3°C, or less than or equal to 2°C, or less than or equal to 1°C. Therefore, the peak position or peak value of the DSC endothermic peak cannot be regarded as absolute.
[0044] The thermogravimetric analysis (TGA) curves of the crystals are subject to experimental error. The endothermic curves or weight loss rates may vary slightly between different machines and between different samples. The experimental error or difference may be less than or equal to 0.004%, 0.003%, 0.002%, or 0.001%. Therefore, the thermogravimetric analysis curves or their weight loss rates cannot be considered absolute.
[0045] In the context of this invention, all figures disclosed herein are approximate values, regardless of whether the words "approximately" or "about" are used. The value of each figure may vary by 1%, 2%, or 5%, etc. When "approximately" is used to describe the 2θ (also known as 2theta or diffraction peak) value of an X-ray powder diffraction peak, "approximately" means that the 2θ value may vary by + / - 0.2 units, + / - 0.1 units, or + / - 0.05 units.
[0046] Specific test results: (1) Instruments for XRPD testing: X-ray powder diffractometer; Instrument model: Rigaku D / max-2500 (Japan); Test method: Cu target Ka, voltage 40KV, current 100mA, test angle 2-40°, step size 8° / min, exposure time 0.2s, light tube slit width 1mm, detector slit width 2.7mm.
[0047] (2) DSC testing instrument: differential calorimeter Instrument Model: Mettler Toledo DSC1 / 500 Test method: heating rate 10℃ / min, protective gas nitrogen flow rate 50mL / min.
[0048] (3) Instruments for TGA testing: thermogravimetric analyzer; Instrument model: Mettler Toledo TGA / DSC (Switzerland); Test method: The atmosphere is nitrogen, and the heating rate is 10℃ / minute.
[0049] (4) Instruments for single-crystal structure analysis: single-crystal diffractometer; Instrument model: Rigaku 007HF XtaLAB P200 (Japan); Test method: Mo Kα rays (l=0.71073 Å) were used for determination; the crystal structure was solved by direct method using OLEX2 software, and the SHELXL-97 program package was used to refine the full matrix least squares method based on the square of the structure amplitude, and the atomic type identification and anisotropic temperature factor correction were completed.
[0050] (5) Instrument used for in vitro solubility test: liquid chromatography; Instrument model: Waters 2695 series high performance liquid chromatography system; Test Method: Under conditions of 25±1℃, the equilibrium solubility of each sample was determined using phosphate buffer solutions at pH 5 and pH 6 (6.80 g of potassium dihydrogen phosphate was dissolved in an appropriate amount of water, adjusted to the target pH with hydrochloric acid or sodium hydroxide solution, and brought to a final volume of 1000 mL). An excess of approximately 20–50 mg of solid sample was weighed and placed in a 10 mL glass bottle. 5 mL of buffer solution was added, the bottle was sealed, and the mixture was shaken at 150 rpm in a constant-temperature shaker for 24 hours in the dark. After standing for 30 minutes, the supernatant was filtered through a 0.45 μm aqueous filter membrane. The concentration of penoxsulam in the filtrate was determined by high-performance liquid chromatography (HPLC). Chromatographic Conditions: C18 reversed-phase column (4.6 mm × 150 mm, 5 μm), mobile phase: acetonitrile-water (containing 0.1% phosphoric acid) v / v 55:45, flow rate: 1.0 mL / min, detection wavelength: 285 nm, column temperature: 30℃, injection volume: 20 μL. Quantification was performed using the standard curve method (linear range 2–300 μg / mL, R²=0.9999), with each sample measured in triplicate. Results were reported as mean ± standard deviation.
[0051] The active pharmaceutical ingredient penoxsulam was analyzed by XRD, DSC, and TGA, and the results are shown in the figures below. Figure 1 and Figure 2 As shown, it can be seen that the active pharmaceutical ingredient penoxsulam is an amorphous type with good crystallinity and a melting point of 216.2℃.
[0052] To better illustrate the present invention and facilitate understanding of its technical solutions, typical but non-limiting embodiments of the present invention are as follows: Example 1
[0053] This embodiment provides a method for preparing multi-component crystals of penoxsulam and nicotinamide. At room temperature (approximately 27°C), 146.9 mg of penoxsulam and 41.9 mg of nicotinamide were weighed in a molar ratio of 1:1. They were first ground separately for 3 min. After mixing, 2 mL of acetonitrile was added, and a second grinding was carried out for 30 min, resulting in a wet powder. The powder was placed at room temperature and dried in a forced-air drying oven at 30°C for 12 h to obtain the sample.
[0054] Weigh 100 mg of the sample obtained above and place it in a 10 mL sample vial. Add 10 mL of dichloromethane at 30 °C to prepare a clear solution, then filter. Transfer the filtrate to another 10 mL sample vial. Allow the solvent to evaporate slowly at room temperature. After 7 days, a transparent bulk single crystal is obtained. The crystal structure diagram obtained after single crystal structure analysis is shown in the figure below. Figure 3 It can be concluded that the single crystal is a multi-component crystal formed by combining penoxsulam and nicotinamide in a molar ratio of 1:1, belonging to the triclinic crystal system, with space group [missing information]. The unit cell parameters are a = 8.6677(2) Å, b = 10.4916(3) Å, c = 13.9465(3) Å, α =93.0866(17)°, β = 99.1415(19)°, γ = 97.684(2)°, unit cell volume V = 1237.26(5) Å 3 , Z = 2.
[0055] The samples obtained above were analyzed using X-ray powder diffraction. The comparison images are shown below. Figure 4 Compared to the active pharmaceutical ingredients penoxsulam and nicotinamide, the samples obtained above exhibit diffraction peaks at 2θ values of 8.4°±0.2°, 10.4°±0.2°, 13.4°±0.2°, 14.4°±0.2°, 15.8°±0.2°, 20.3°±0.2°, 21.2°±0.2°, 24.7°±0.2°, 25.6°±0.2°, and 26.5°±0.2° in their X-ray powder diffraction patterns. Furthermore, the XRD patterns fitted with single-crystal structure data are consistent with... Figure 4 Consistent.
[0056] Differential scanning calorimetry and thermogravimetric analysis were performed on the samples obtained above. The results are shown in [Figure number missing]. Figure 5 ,from Figure 5 It can be seen that the differential scanning calorimetry spectrum shows a melting endothermic peak at 156.4℃.
[0057] In summary, the sample obtained above is a multi-component crystal of penoxsulam and nicotinamide, representing a novel solid form of penoxsulam. Example 2
[0058] This embodiment provides a method for preparing multi-component crystals of penoxsulam and nicotinamide. At room temperature (approximately 27°C), 146.9 mg of penoxsulam and 41.8 mg of nicotinamide were weighed at a molar ratio of 1:1. They were first ground separately for 3 minutes. After mixing, 2 mL of methanol was added, and a second grinding was carried out for 30 minutes to obtain a wet powder. The powder was placed at room temperature and dried in a forced-air drying oven at 30°C for 12 hours to obtain the sample.
[0059] The above samples were subjected to single-crystal structure analysis, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis (same as in Example 1), and the test results were found to be the same as in Example 1. Example 3
[0060] This embodiment provides a method for preparing multi-component crystals of penoxsulam and nicotinamide. At room temperature (approximately 27°C), 147.0 mg of penoxsulam and 41.9 mg of nicotinamide were weighed in a molar ratio of 1:1. They were first ground separately for 3 min. After mixing, 2 mL of acetone was added, and a second grinding was carried out for 30 min, resulting in a wet powder. The powder was placed at room temperature and dried in a forced-air drying oven at 30°C for 12 h to obtain the sample.
[0061] The above samples were subjected to single-crystal structure analysis, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis (same as in Example 1), and the test results were found to be the same as in Example 1. Example 4
[0062] This embodiment provides a method for preparing multi-component crystals of penoxsulam and nicotinamide. At room temperature (approximately 27°C), 104.1 mg of penoxsulam and 26.3 mg of nicotinamide are weighed at a molar ratio of 1:1 and placed in a 10 mL sample bottle. A suspension is prepared by adding 3 mL of dichloromethane solvent. The suspension is then stirred at room temperature for 24 hours, filtered, and the solid is dried in a 40°C forced-air drying oven for 12 hours to obtain the sample.
[0063] The above samples were subjected to single-crystal structure analysis, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis (same as in Example 1), and the test results were found to be the same as in Example 1. Example 5
[0064] This embodiment provides a method for preparing multi-component crystals of penoxsulam and nicotinamide. At 50°C, 104.1 mg of penoxsulam and 26.3 mg of nicotinamide are weighed at a molar ratio of 1:1 and placed in a 10 mL sample bottle. 8 mL of methanol solvent is added to form a clear solution. Water is added dropwise as a poor solvent, and the mixture is stirred, filtered, and the solid is dried in a 40°C forced-air drying oven for 12 hours to obtain the sample.
[0065] The above samples were subjected to single-crystal structure analysis, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis (same as in Example 1), and the test results were found to be the same as in Example 1. Example 6
[0066] This embodiment provides a method for preparing multi-component crystals of penoxsulam and isonicotinamide. At room temperature (approximately 27°C), 146.9 mg of penoxsulam and 41.9 mg of isonicotinamide were weighed at a molar ratio of 1:1. They were first ground separately for 3 minutes. After mixing, 2 mL of ethanol was added, and a second grinding was carried out for 30 minutes to obtain a wet powder. The powder was placed at room temperature and dried in a forced-air drying oven at 30°C for 12 hours to obtain the sample.
[0067] Weigh 100 mg of the sample obtained above and place it in a 10 mL sample vial. Add 20 mL of ethanol at 40 °C to prepare a clear solution, then filter. Transfer the filtrate to another 10 mL sample vial. Allow the solvent to evaporate slowly at room temperature. After 28 days, a transparent bulk single crystal is obtained. The crystal structure diagram obtained after single crystal structure analysis is shown in the figure below. Figure 6 It can be concluded that the single crystal is a multi-component crystal formed by combining penoxsulam and isonicotinamide in a molar ratio of 1:1, belonging to the triclinic crystal system, with space group [missing information]. The unit cell parameters are a = 8.5668(2) Å, b = 12.3085(11) Å, c = 12.6054(12) Å, α = 70.212(9)°, β = 86.276(5)°, γ = 80.245(5)°, cell volume V = 1232.56(18) Å 3 ,Z = 2.
[0068] The samples obtained above were analyzed using X-ray powder diffraction. The comparison images are shown below. Figure 7 Compared to the active pharmaceutical ingredients penoxsulam and isonicotinamide, the sample obtained above exhibits diffraction peaks at 2θ values of 12.0°±0.2°, 12.9°±0.2°, 15.4°±0.2°, 18.9°±0.2°, 22.4°±0.2°, 28.3°±0.2°, and 32.5°±0.2° in its X-ray powder diffraction pattern; moreover, the XRD pattern obtained after fitting single-crystal structure data is consistent with... Figure 7 Consistent.
[0069] Differential scanning calorimetry and thermogravimetric analysis were performed on the samples obtained above. The results are shown in [Figure number missing]. Figure 8 ,from Figure 8 It can be seen that the differential scanning calorimetry spectrum shows a melting endothermic peak at 126.3℃.
[0070] In summary, the samples obtained above are multi-component crystals of penoxsulam and isonicotinamide, representing a novel solid form of penoxsulam. Example 7
[0071] This embodiment provides a method for preparing multi-component crystals of penoxsulam and isonicotinamide. At room temperature (approximately 27°C), 146.9 mg of penoxsulam and 41.7 mg of isonicotinamide were weighed at a molar ratio of 1:1. They were first ground separately for 3 minutes. After mixing, 2 mL of tetrahydrofuran was added, and a second grinding was carried out for 30 minutes to obtain a wet powder. The powder was placed at room temperature and dried in a forced-air drying oven at 30°C for 12 hours to obtain the sample.
[0072] The above samples were subjected to single-crystal structure analysis, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis (same as in Example 6), and the test results were found to be the same as in Example 6. Example 8
[0073] This embodiment provides a method for preparing multi-component crystals of penoxsulam and isonicotinamide. At room temperature (approximately 27°C), 104.1 mg of penoxsulam and 26.3 mg of isonicotinamide are weighed at a molar ratio of 1:1 and placed in a 10 mL sample bottle. A suspension is prepared by adding 3 mL of dichloromethane solvent. The suspension is then stirred at room temperature for 24 hours, filtered, and the solid is dried in a 40°C forced-air drying oven for 12 hours to obtain the sample.
[0074] The above samples were subjected to single-crystal structure analysis, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis (same as in Example 6), and the test results were found to be the same as in Example 6. Example 9
[0075] This embodiment provides a method for preparing multi-component crystals of penoxsulam and isonicotinamide. At 50°C, 104.1 mg of penoxsulam and 26.3 mg of isonicotinamide were weighed at a molar ratio of 1:1 and placed in a 10 mL sample bottle. 8 mL of methanol was added to form a clear solution. Ethyl acetate was added dropwise as a poor solvent. The mixture was stirred, filtered, and the solid was dried in a 40°C oven for 12 hours to obtain the sample.
[0076] The above samples were subjected to single-crystal structure analysis, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis (same as in Example 6), and the test results were found to be the same as in Example 6. Example 10
[0077] This embodiment provides a method for preparing multi-component crystals of penoxsulam and isonicotinamide. At 50°C, 104.1 mg of penoxsulam and 26.3 mg of isonicotinamide were weighed at a molar ratio of 1:1 and placed in a 10 mL sample bottle. 8 mL of methanol solvent was added to form a clear solution. The solution was cooled to 20°C, and a solid precipitated out. The solution was stirred, filtered, and dried in a 40°C forced-air drying oven for 12 hours to obtain the sample.
[0078] The above samples were subjected to single-crystal structure analysis, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis (same as in Example 6), and the test results were found to be the same as in Example 6.
[0079] The solubility of the active pharmaceutical ingredient penoxsulam and the samples obtained in the above examples were tested, and the test results are shown in Table 1.
[0080] Table 1. Comparison of equilibrium solubility of different samples in different pH buffer solutions
[0081] Note: Solubility data are the average of three parallel determinations ± standard deviation. There were no significant differences in solubility for the same crystal form obtained by other methods. The solubility enhancement factor refers to the factor by which the solubility of the obtained sample compared to the active pharmaceutical ingredient penflusulfonamide is increased under the same pH conditions.
[0082] As shown in Table 1, the formation of multi-component crystals of penflusulfonamide with pyridinecarboxamide ligands (such as nicotinamide and isonicotinamide) improves the solubility of penflusulfonamide technical in weakly acidic solutions and provides a basis for improving its bioavailability and herbicidal effect. The multi-component crystals formed by pyridinecarboxamide ligands and penflusulfonamide have significantly improved solubility under weakly acidic conditions (pH 5). Moreover, compared with nicotinamide, the use of isonicotinamide as a ligand increases the solubility by about 3.8 times under weakly acidic conditions (pH 5).
[0083] The applicant declares that the above description is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention fall within the protection and disclosure scope of the present invention.
Claims
1. A multi-component crystal of penoxsulam and a pyridinecarboxamide ligand, characterized by, The molar ratio of penoxsulam to pyridinecarboxamide ligands in the multi-component crystal of penoxsulam and pyridinecarboxamide ligands is 1:
1.
2. The multi-component crystal of penoxsulam and pyridinecarboxamide ligands according to claim 1, characterized in that, The pyridine carboxamide ligands include at least one of nicotinamide and isonicotinamide.
3. The multi-component crystal of penoxsulam and pyridinecarboxamide ligands according to claim 1, characterized in that, The pyridinecarboxamide ligand is nicotinamide; the multi-component crystal of penoxsulam and the pyridinecarboxamide ligand is a multi-component crystal formed by combining penoxsulam and nicotinamide in a molar ratio of 1:1, belonging to the triclinic crystal system, with space group [missing information]. The unit cell parameters are a = 8.6677(2) Å, b = 10.4916(3) Å, c = 13.9465(3) Å, α =93.0866(17)°, β = 99.1415(19)°, γ = 97.684(2)°, unit cell volume V = 1237.26(5) Å 3 , Z = 2.
4. The multi-component crystal of penoxsulam and pyridinecarboxamide ligands according to claim 3, characterized in that, The multi-component crystal formed by combining penoxsulam and nicotinamide in a 1:1 molar ratio exhibits diffraction peaks at 2θ values of 8.4°±0.2°, 10.4°±0.2°, 13.4°±0.2°, 14.4°±0.2°, 15.8°±0.2°, 20.3°±0.2°, 21.2°±0.2°, 24.7°±0.2°, 25.6°±0.2°, and 26.5°±0.2° in the X-ray powder diffraction pattern; and a characteristic melting peak is observed at 156.4±2℃ in the differential scanning calorimetry (DSC) pattern.
5. The multi-component crystal of penoxsulam and pyridinecarboxamide ligands according to claim 1, characterized in that, The pyridinecarboxamide ligand is isonicotinamide; the multi-component crystal of penoxsulam and the pyridinecarboxamide ligand is a multi-component crystal formed by combining penoxsulam and isonicotinamide in a molar ratio of 1:1, belonging to the triclinic crystal system, with space group [missing information]. The unit cell parameters are a = 8.5668(2) Å, b = 12.3085(11) Å, c = 12.6054(12) Å, α =70.212(9)°, β = 86.276(5)°, γ = 80.245(5)°, cell volume V = 1232.56(18) Å 3 , Z = 2.
6. The multi-component crystal of penoxsulam and pyridinecarboxamide ligands according to claim 5, characterized in that, The multi-component crystal formed by combining penoxsulam and isonicotinamide in a molar ratio of 1:1 exhibits diffraction peaks at 2θ values of 12.0°±0.2°, 12.9°±0.2°, 15.4°±0.2°, 18.9°±0.2°, 22.4°±0.2°, 28.3°±0.2°, and 32.5°±0.2° in the X-ray powder diffraction pattern; and a characteristic melting peak is observed at 126.3±2℃ in the differential scanning calorimetry (DSC) pattern.
7. The method for preparing multi-component crystals of penoxsulam and pyridinecarboxamide ligands according to any one of claims 1-6, characterized in that, The preparation methods include grinding reaction crystallization or solution crystallization.
8. The preparation method according to claim 7, characterized in that, The grinding reaction crystallization method satisfies at least one of the following (1)-(6): (1) Weigh penoxsulam and pyridine carboxamide ligands at a molar ratio of 1:1, grind them separately for the first time, mix them and add a good solvent, grind them for the second time, and dry them to obtain multi-component crystals of penoxsulam and pyridine carboxamide ligands; (2) Based on a total addition of 100 mg of penoxsulam and pyridine carboxamide ligands, the amount of good solvent added is 0.1-3 mL; (3) The good solvent includes any one or a combination of at least two of acetonitrile, acetone, methanol, dichloromethane, ethanol or tetrahydrofuran; (4) The first grinding time is 2-10 min; (5) The second grinding time is 20-40 min; (6) The drying temperature is 25-60℃.
9. The preparation method according to claim 7, characterized in that, The solution crystallization method satisfies at least one of the following (a)-(h): (a) Weigh penoxsulam and pyridine carboxamide ligands at a molar ratio of 1:1, add them to a good solvent to form a suspension, stir, separate the solid and liquid and dry to obtain multi-component crystals of penoxsulam and pyridine carboxamide ligands; (b) Weigh penoxsulam and pyridine carboxamide ligands at a molar ratio of 1:1, add them to a good solvent to form a clear solution, add a poor solvent, stir, separate the solid and liquid and dry to obtain multi-component crystals of penoxsulam and pyridine carboxamide ligands; (c) Weigh penoxsulam and pyridine carboxamide ligands at a molar ratio of 1:1, add them to a good solvent to form a clear solution, stir, cool and cool until solid precipitates, separate the solid and liquid and dry to obtain multi-component crystals of penoxsulam and pyridine carboxamide ligands; (d) Based on a total addition of 100 mg of penoxsulam and pyridine carboxamide ligands, the amount of good solvent added is 1-20 mL; (e) The good solvent includes any one or a combination of at least two of acetonitrile, acetone, methanol, dichloromethane, ethanol or tetrahydrofuran; (f) The undesirable solvents include any one or a combination of at least two of ethyl acetate, isopropanol, water or methyl tert-butyl ether; (g) The drying temperature is 25-60℃; (h) The stirring rate is 100-500 rpm.
10. The application of a multi-component crystal of penoxsulam and pyridinecarboxamide ligands, characterized in that, The multi-component crystals of penoxsulam and pyridine carboxamide ligands as described in any one of claims 1-6, or the multi-component crystals of penoxsulam and pyridine carboxamide ligands prepared by the preparation method described in any one of claims 7-9, are applied to herbicides.
